Valopicitabine dihydrochloride | 640725-71-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Valopicitabine dihydrochloride
• 英文别名: [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate;dihydrochloride
• CAS: 640725-71-9
• 化学式: C15H26Cl2N4O6
• 分子量: 429.3
• InChiKey: XENHXZMAOSTXGD-DSMKLBDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  161
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Antiviral Agents
  申请人：Attenni Barbara

  公开号：US20100152128A1

  公开（公告）日：2010-06-17

  A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.

  公式（I）的化合物及其药用盐；含有该化合物的组合物及其在医学上的用途，特别是用于治疗或抑制HCV感染，以及制备该化合物的方法。
• ANTIVIRAL AGENTS
  申请人：Surnma Vincenzo

  公开号：US20120010164A1

  公开（公告）日：2012-01-12

  Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; as defined herein, are described for use in the prevention and/or treatment of HCV infections. Novel compounds of the formula (I) and pharmaceutical formulations containing them are also described.

  结构式（I）的化合物及其药用盐；如本文所定义，用于预防和/或治疗HCV感染。还描述了公式（I）的新化合物以及含有它们的药物配方。
• NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES
  申请人：Avolio Salvatore

  公开号：US20110306573A1

  公开（公告）日：2011-12-15

  Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; wherein R 1 ; R 2 ; R 3 ; Q 1 and Q 2 are as defined herein, processes for their preparation; pharmaceutical compositions containing them and their use in medicine, in particular the treatment or prevention of HCV infections, are disclosed.

  结构式(I)的化合物及其药用盐；其中R1、R2、R3、Q1和Q2如本文所定义，其制备方法；含有它们的药物组合物以及它们在医学中的应用，特别是用于治疗或预防HCV感染，已被披露。
• Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection
  申请人：MacCoss Malcolm

  公开号：US20100234316A1

  公开（公告）日：2010-09-16

  The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.

  本发明提供了结构式（I）的核苷酸芳基磷酰胺酯，这些化合物是RNA依赖性RNA病毒聚合酶抑制剂的前体。这些化合物是RNA依赖性RNA病毒复制抑制剂的前体，对于治疗RNA依赖性RNA病毒感染非常有用。它们特别适用作为乙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体，和/或用于治疗乙型肝炎感染。本发明还描述了含有这种核苷酸芳基磷酰胺酯的药物组合物，单独或与其他针对RNA依赖性RNA病毒感染，特别是HCV感染的药剂结合使用。还公开了使用本发明的核苷酸芳基磷酰胺酯来抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION
  申请人：Meppen Malte

  公开号：US20100022468A1

  公开（公告）日：2010-01-28

  The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside cyclic phosphoramidates of the present invention.

  本发明提供了结构式（I）的核苷酸环磷酰胺，它们是RNA依赖性RNA病毒聚合酶抑制剂的前体。这些化合物是RNA依赖性RNA病毒复制的抑制剂的前体，并且可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体和/或用于治疗丙型肝炎感染。本发明还描述了仅含有这种核苷酸环磷酰胺或与其他对RNA依赖性RNA病毒感染，特别是HCV感染活性的药物组合的制药组合物。本发明还公开了使用本发明的核苷酸环磷酰胺抑制RNA依赖性RNA聚合酶，抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。